Categories: Acquisition

Emami raises Rs. 900 cr to part-fund Kesh King acquisition

Deal to bring in Kesh King-branded ayurvedic hair oil, capsules and shampoo formulations

Kolkata, June 20, 2015:

FMCG player Emami Ltd has raised around Rs. 900 crore debt to partially fund the Rs. 1,651-crore acquisition of Kesh King hair-care branded products from Sanjev Juneja of SBS Biotech.

This is the biggest deal for Emami so far. Earlier, it had acquired the controlling stake in Zandu Pharmaceuticals for around Rs. 700 crore.

“We have raised Rs. 800-900 crore through fresh borrowings. The balance is financed through internal resources,” Harsh Agarwal, Director, told BusinessLine .

Boost to bottom-line

The deal has brought in Kesh King-branded ayurvedic hair oil, capsules and shampoo formulations into the Emami-fold. Kesh Pari hair oil, an associate fighter brand, was also a part of the deal.

Justifying the high cost acquisition, Agarwal maintained that Kesh King products have a higher profit margin when compared to the existing products of Emami.

So far, the FMCG major’s portfolio (hair-care) include the “Navratna Cool Oil” and “Seven Oils in One” (a hair damage control offering).

The hair oil from Kesh King will be more or less similar to Emami’s Seven Oils offering, sources said.

But, according to Agarwal, Kesh King’s products are priced “higher”.

With ayurvedic only offerings in what the company calls an “affordable segment”, the brand competes with the likes of “Sesa” and “Anoop” in the hair oil segments.

Companies like Biotique, compete in the premium segment of the market with similar offerings across shampoos, hair-oils and conditioners.

National presence

According to Agarwal, these medicinal products have a strong presence in the northern and western regions.

The focus will be to expand the brand’s presence in eastern and southern regions by leveraging Emami’s distribution network. There would be no price revision either, he confirmed. The acquisition does not include takeover of any manufacturing facility.

Products will, at present, be sourced from SBS Biotech’s facility.

“We have decided to go in for contract manufacturing. However, we have an option of manufacturing the products in future,” he said.

There, however, are no “immediate” plans to re-brand Kesh King.

According to Agarwal, it will take some time before the company takes a call on the matter. Business Line

The Pharma Times News Bureau

Recent Posts

CARE Hospitals, Nampally, Hosts the 12th National Infection Prevention and Control (IPC) Certificate Program

Hyderabad, November 22, 2024: CARE Hospitals, Nampally, successfully hosted the 12th National Infection Prevention and Control (IPC)…

22 hours ago

61-Year-Old African Doctor morbidly Obese successfully treated for End-Stage Renal Disease via Robot-Assisted Kidney Transplant at Fortis Hospital Cunningham Road

Bengaluru, November 22, 2024: Fortis Hospital, Cunningham Road successfully performed a life-enhancing robot-assisted kidney transplant on 61-year-old…

22 hours ago

Lung Cancer Awareness Month

By Dr. C N Patil, HOD and Lead Consultant - Medical Oncology & Haemato-Oncology, Aster…

2 days ago

Unmasking COPD: The Silent Respiratory Threat of Smoking

By  Dr. Pavan Yadav, Lead Consultant - Interventional Pulmonology & Lung Transplantation, Aster RV Hospital …

2 days ago

Khazi India Foundation to Host Expert Cardiac Consultations in Adoni

Kurnool, November 20, 2024: Adoni, Andhra Pradesh, – The Khazi India Foundation is pleased to…

3 days ago

Aakash Healthcare Celebrates Children’s Day with Kids from Choti Si Khushi

New Delhi, November 20, 2024: Aakash Healthcare marked this year’s Children’s Day with a joyful…

3 days ago